PD-L1 IHC 28-8 pharmDx

Nchi: Australia

Lugha: Kiingereza

Chanzo: Department of Health (Therapeutic Goods Administration)

Inapatikana kutoka:

Agilent Technologies Australia Pty Ltd

Darasa:

Class 3

Viwandani na:

Agilent Technologies Inc 5301 Stevens Creek Boulevard, Santa Clara, CA, 95051 United States Of America

Eneo la matibabu:

CT1056 - Immunohistology cell marker IVDs

Matibabu dalili:

PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) cancer tissues using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-squamous non-small cell lung cancer (nsNSCLC), melanoma, and esophageal squamous cell carcinoma (ESCC) tissues. It is indicated as an aid in identifying ESCC patients with tumour cell PD-L1 expression ? 1% for treatment with OPDIVO? (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy or OPDIVO? (nivolumab) in combination with YERVOY? (ipilimumab).

Idhini hali ya:

A

Idhini ya tarehe:

2023-08-17